Global and United States Bioequivalent Peptide Drugs Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States Bioequivalent Peptide Drugs Market Report & Forecast 2024-2034
A bioequivalent peptide drug is one that has similar structure and function, and exhibits similar pharmacokinetic and pharmacodynamic properties in vivo to the original brand drug or an approved reference product. These drugs are usually synthesized through genetic recombination technology and undergo rigorous research and development and approval procedures.
Market Analysis and InsightsGlobal and United States Bioequivalent Peptide Drugs Market
This report focuses on global and United States Bioequivalent Peptide Drugs market, also covers the segmentation data of other regions in regional level and county level.
The global Bioequivalent Peptide Drugs revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period (2024-2034).
The development and production of bioequivalent peptide drugs usually requires detailed comparison and analysis, including in vitro and in vivo experimental evaluation, and comparison of clinical trial data. Bioequivalent peptide drugs have a wide range of applications in drug replacement, therapeutic expansion, and biosimilars.
Global Bioequivalent Peptide Drugs Scope and Market Size
Bioequivalent Peptide Drugs market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Bioequivalent Peptide Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For United States market, this report focuses on the Bioequivalent Peptide Drugs market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in United States.
Eli Lilly and Company
Alvogen
Pfenex
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Ambio Pharmaceuticals
Jiangsu Sinopep Allsino Biopharmaceutical
Shanghai Shyndec Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Shanghai United Cell Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide Biotechnology
Segment by Type
Teriparatide(Forteo)
Teduglutide(Gattex)
Liraglutide(Victoza)
Short Bowel Syndrome
Osteoporosis
Type 2 Diabetes
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Bioequivalent Peptide Drugs definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Bioequivalent Peptide Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Bioequivalent Peptide Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bioequivalent Peptide Drugs sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Market Analysis and InsightsGlobal and United States Bioequivalent Peptide Drugs Market
This report focuses on global and United States Bioequivalent Peptide Drugs market, also covers the segmentation data of other regions in regional level and county level.
The global Bioequivalent Peptide Drugs revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period (2024-2034).
The development and production of bioequivalent peptide drugs usually requires detailed comparison and analysis, including in vitro and in vivo experimental evaluation, and comparison of clinical trial data. Bioequivalent peptide drugs have a wide range of applications in drug replacement, therapeutic expansion, and biosimilars.
Global Bioequivalent Peptide Drugs Scope and Market Size
Bioequivalent Peptide Drugs market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Bioequivalent Peptide Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For United States market, this report focuses on the Bioequivalent Peptide Drugs market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in United States.
By Company
Eli Lilly and Company
Alvogen
Pfenex
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Ambio Pharmaceuticals
Jiangsu Sinopep Allsino Biopharmaceutical
Shanghai Shyndec Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Shanghai United Cell Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide Biotechnology
Segment by Type
Teriparatide(Forteo)
Teduglutide(Gattex)
Liraglutide(Victoza)
Segment by Application
Short Bowel Syndrome
Osteoporosis
Type 2 Diabetes
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Bioequivalent Peptide Drugs definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Bioequivalent Peptide Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Bioequivalent Peptide Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bioequivalent Peptide Drugs sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices